Credit Suisse raised its price target for BioMarin (BMRN) to $133 from $131, while nudging up valrox Probability of Success to 75% from 65%. The firm thinks the valoctocogene roxaparvovec data largely alleviates the valrox durability overhang and re-awakens an M&A thesis on BioMarin on the value of its gene therapy platform. The company's de-risked Phase 3 valrox program and established mfg infrastructure put the company's gene tx assets in the valuation range up to that established by the AveXis (AVXS) and Spark Therapeutics (ONCE) transactions, Credit Suisse contends.